CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Silverman who wrote (138)	5/4/1997 2:14:00 PM
From: Miljenko Zuanic	of 675

John, Paul, James, and other: I think that Dr. E. R. Gamzu, when he mentioned new drug and research program, was actually announcing small molecules that can antagonize the activity of neuregulins-potential use in breast, ovarian and brain cancers. This project is with collaboration with ProsCure. May be they have new partner? Vertex has research project on CNS: neurophilin (stimulation of the nerve grow) and Caspase CPP32 inhibitor (neuroprotective factor). I am little surprise with CNSI intention for interim results. Because if they can't break blind, any analysis is unreliable, it can't be associated with treatment: drug or placebo. If I have time I will tried to clear this. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next